Already a member or subscriber? Sign in now

Previous article
Tools to Help Family Physicians Advocate for Privileging and Credentialing for Their Qualified Scope of Practice
Mar / Apr 2026
Next article
Enhancing Access and Payment Through Proper Use of Modifiers

Understanding the Results of Randomized Controlled Trials: A Refresher

KATE ROWLAND, MD
MARK EBELL, MD

FPM. 2026;33(2):27-31.

Author disclosures: no relevant financial relationships.

This content conforms to AAFP criteria for CME.

A few quick calculations can help you interpret and apply study results to improve patient care.

Dr. Rowland is an associate professor in the Department of Family and Preventive Medicine, Rush Medical College, Chicago.

Dr. Ebell is a professor in the Department of Family Medicine, Michigan State University, East Lansing, Mich.

Author disclosures: no relevant financial relationships.

  1. 1.Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hyper-tensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
  2. 2.Ebell MH, Barry HC, Baduni K, Grasso G. Clinically important benefits and harms of monoclonal antibodies targeting amyloid for the treatment of Alzheimer disease: a systematic review and meta-analysis. Ann Fam Med. 2024;22(1):50-62.
  3. 3.Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.
  4. 4.Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407-415.
  5. 5.Schrag A, Schott JM; Alzheimer's Disease Neuroimaging Initiative. What is the clinically relevant change on the ADAS-Cog? J Neurol Neurosurg Psychiatry. 2012;83(2):171-173.
  6. 6.Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492-1495.
Previous article
Tools to Help Family Physicians Advocate for Privileging and Credentialing for Their Qualified Scope of Practice
Mar / Apr 2026
Next article
Enhancing Access and Payment Through Proper Use of Modifiers

Latest issue

May / June 2026

May / June 2026

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.